08 4月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
29 3月 2024 by admin in UncategorizedComments 礼邦医药在研创新药物 AP303 获得美国食品药品监督管理局(FDA)孤儿药 资格认定, 用于治疗常染色体显性多囊肾病(ADPKD)
26 3月 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
06 3月 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Patricia Allen to its Board of Directors
07 2月 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Kerry Benenato, Ph.D., as Chief Platform Officer
29 1月 2024 by admin in UncategorizedComments 原启生物宣布 FDA 批准其靶向 GPRC5D CAR-T 产品 OriCAR-017 的 IND 申请，该产品用于治疗复发/难治性 多发性骨髓瘤
25 1月 2024 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
18 1月 2024 by admin in UncategorizedComments NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
15 1月 2024 by admin in UncategorizedComments Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
04 1月 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board
03 1月 2024 by admin in UncategorizedComments Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines
19 12月 2023 by admin in UncategorizedComments Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
13 12月 2023 by admin in UncategorizedComments Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan- inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
06 12月 2023 by admin in UncategorizedComments Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
06 12月 2023 by admin in UncategorizedComments Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
05 12月 2023 by admin in UncategorizedComments Adcentrx Announces Extension of Series A+ Financing to $51 Million
05 12月 2023 by admin in UncategorizedComments Zenas 任命 Jennifer Fox 为首席商务官兼 CFO,Tanya Fischer 为研发主管兼 CMO，以加强行政领导层
04 12月 2023 by admin in UncategorizedComments Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
15 11月 2023 by admin in UncategorizedComments ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
19 10月 2023 by admin in UncategorizedComments Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to form Sail
02 10月 2023 by admin in UncategorizedComments Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
19 9月 2023 by admin in UncategorizedComments Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
12 9月 2023 by admin in UncategorizedComments 科越医药在 2023 年第 29 届国际补体大会上公布了 KP104 I 期 SYNERGY-1 临床试验 的 完整数据，以及与 Lübeck 大学合作在自身免疫性皮肤病模型中的临床前研究成果
07 9月 2023 by admin in UncategorizedComments NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
05 9月 2023 by admin in UncategorizedComments Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
04 9月 2023 by admin in UncategorizedComments Crescendo Biologics Wins Significant European Patent Office Ruling Related to the Engineering of Immunoglobulin Therapeutics
14 8月 2023 by admin in UncategorizedComments Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
24 7月 2023 by admin in UncategorizedComments Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
11 7月 2023 by admin in UncategorizedComments Adicet Announces Appointment of Katie Peng to the Board of Directors
09 5月 2023 by admin in UncategorizedComments Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
27 4月 2023 by admin in UncategorizedComments Crescendo Biologics appoints Angus Hone as Chief Financial Officer
